NCT06600321 2026-03-31
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Alnylam Pharmaceuticals
Phase 1 Recruiting
Alnylam Pharmaceuticals
Dana-Farber Cancer Institute
Essen Biotech
University College, London
Second Affiliated Hospital of Guangzhou Medical University